SINGAPORE – Media OutReach Newswire – February 4, 2024 – On World Cancer Day, a consortium called Asia Pacific Policy Review and Engagement for Lung Cancer, known as ASPIRE, is officially launching to fight against lung cancer, one of the leading causes of cancer deaths worldwide. Asia-Pacific region. The group will work with governments, agencies, NGOs and patient groups to improve health outcomes for lung cancer patients in Asia Pacific.
Lung cancer has a significant health and economic impact in the region. It is the most common cancer, responsible for approximately 1 million deaths per year, and is expected to reach more than 1.8 million by 2040.1
Access to lung cancer screening, diagnosis and treatment varies between countries, where local challenges are often unique. ASPIRE for Lung Cancer aims to improve access in the region by bringing together multidisciplinary experts and advocating for policy changes tailored to local needs.
As part of this effort, a plan to sign a Memorandum of Understanding for collaborations with the Asia-Pacific Lung Cancer Coalition (APCLC) has been developed. The APCLC, being a multidisciplinary group led by physicians and other stakeholders, provides academic information, clinical perspectives and expertise in conducting studies in the APAC region.
“Lung cancer is often diagnosed at an advanced stage, when treatment options are limited and survival is lowest,” says Dr. Herbert Loong, associate professor at the Department of Clinical Oncology at the Chinese University of China. Hong Kong and President of the APCLC. “With technological advances in early detection of lung cancer and significantly improved treatment outcomes, our goal is to raise awareness and encourage governments in the APAC region to prioritize this disease. Achieving this goal requires coordinated efforts from multiple stakeholders. synergize our efforts with like-minded collaborators, such as ASPIRE, to advance this agenda.”
Launched on World Cancer Day, ASPIRE highlights a commitment to advocate for improved overall care, promote public and patient awareness, and encourage governments to prioritize and address gaps existing in lung cancer services. In line with the World Cancer Day 2024 campaign theme, “Closing the Care Gap”, ASPIRE for Lung Cancer aims to make a substantial contribution to tackling disparities in access to cancer services. quality in lung cancer.
The Consortium will address lung cancer challenges in Asia-Pacific through four approaches:
-
Advocate for lung cancer to be a priority in government action plans and budgets
-
Engage in multilateral consortium efforts to improve screening, diagnosis, treatment and care
-
Mobilize resources for evidence generation and policy implementation
-
Providing a platform for policy discussions and campaigns on lung cancer
ASPIRE for Lung Cancer is supported by five financial members: Amgen, AstraZeneca, Johnson & Johnson, Roche Diagnostics and Siemens Healthineers. The secretariat is managed by EquiHealth, a non-profit organization specializing in engagements across the health ecosystem.
Will Brown, Director of ASPIRE at EquiHealth, said: “Despite being the highest burden cancer in Asia, we often see that lung cancer is no longer a priority in policy and health decisions. funding. Advances across the continuum of patient care, from prevention and screening to diagnosis and treatment, mean more can be done for lung cancer patients with the right policy approach. We are proud to launch the ASPIRE initiative and look forward to partnering with more like-minded organizations to drive the policy agenda on lung cancer in the APAC region.
To commemorate this milestone, ASPIRE for Lung Cancer will host an official launch event on the 20th.th February 2024 in Singapore. This launch event will serve as a platform to highlight its goals, share ideas and lay the foundation for collaborative efforts.
ASPIRE for Lung Cancer is grateful for the support received so far and looks forward to making a positive impact on lung cancer patients in the Asia-Pacific region.
For more information about ASPIRE for lung cancer, please visit:
Website :
www.aspirelungcancer.com
LinkedIn:
https://www.linkedin.com/showcase/aspire-for-lung-cancer
The references
-
Allemani C, Matsuda T, Di Carlo V et al.; CONCORD working group. Global Surveillance of Cancer Survival Trends 2000-14 (CONCORD-3): analysis of individual records of 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. March 17, 2018 ;391
https://www.aspirelungcancer.com
https://www.linkedin.com/showcase/aspire-for-lung-cancer
Hashtag: #WorldCancerDay2024 #CloseTheCareGap #ASPIREforLungCancer #LungCancer
The issuer is solely responsible for the content of this announcement.
